Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Dec;50(2):362-371.
doi: 10.1038/s41386-024-01972-6. Epub 2024 Aug 23.

Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants

Isabelle Straumann #  1   2 , Isidora Avedisian #  1   2 , Aaron Klaiber  1   2 , Nimmy Varghese  3   4 , Anne Eckert  3   4 , Deborah Rudin  1   2 , Dino Luethi  1   2 , Matthias E Liechti  5   6
Affiliations
Randomized Controlled Trial

Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants

Isabelle Straumann et al. Neuropsychopharmacology. 2024 Dec.

Abstract

Racemic 3,4-methylenedioxymethamphetamine (MDMA) acutely increases mood, feelings of empathy, trust, and closeness to others and is investigated to assist psychotherapy. Preclinical research indicates that S-MDMA releases monoamines and oxytocin more potently than R-MDMA, whereas R-MDMA more potently stimulates serotonin 5-hydroxytryptamine-2A receptors. S-MDMA may have more stimulant properties, and R-MDMA may be more psychedelic-like. However, acute effects of S- and R-MDMA have not been examined in a controlled human study. We used a double-blind, randomized, placebo-controlled, crossover design to compare acute effects of MDMA (125 mg), S-MDMA (125 mg), R-MDMA (125 mg and 250 mg), and placebo in 24 healthy participants. Outcome measures included subjective, autonomic, and adverse effects, pharmacokinetics, and plasma oxytocin, prolactin, and cortisol concentrations. S-MDMA (125 mg) induced greater subjective effects ("stimulation," "drug high," "happy," "open") and higher increases in blood pressure than R-MDMA (both 125 and 250 mg) and MDMA (125 mg). Unexpectedly, R-MDMA did not produce more psychedelic-like effects than S-MDMA. S-MDMA increased plasma prolactin more than MDMA, and S-MDMA increased plasma cortisol and oxytocin more than MDMA and R-MDMA. The plasma elimination half-life of S-MDMA was 4.1 h after administration. The half-life of R-MDMA was 12 and 14 h after the administration of 125 and 250 mg, respectively. Half-lives for S-MDMA and R-MDMA were 5.1 h and 11 h, respectively, after racemic MDMA administration. Concentrations of the CYP2D6-formed MDMA-metabolite 4-hydroxy-3-methoxymethamphetamine were lower after R-MDMA administration compared with S-MDMA administration. The pharmacokinetic findings are consistent with the R-MDMA-mediated inhibition of CYP2D6. Stronger stimulant-like effects of S-MDMA in the present study may reflect the higher potency of S-MDMA rather than qualitative differences between S-MDMA and R-MDMA. Equivalent acute effects of S-MDMA, MDMA, and R-MDMA can be expected at doses of 100, 125, and 300 mg, respectively, and need to be investigated.Trial registration: ClinicalTrials.gov identifier: NCT05277636.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MEL is a consultant for Mind Medicine, Inc. The other authors declare no conflicts of interest. Knowhow and data associated with this work are owned by the University Hospital Basel and were licensed by Mind Medicine, Inc. Mind Medicine, Inc., had no role in planning or conducting the present study or writing the publication.

Figures

Fig. 1
Fig. 1. Acute subjective effects of 125 mg MDMA, 125 mg S-MDMA, 125 mg R-MDMA, and 250 mg R-MDMA on the Visual Analog Scale (VAS).
S-MDMA produced overall stronger subjective responses than MDMA, with significant differences in “bad drug effects,” “alteration of vision,” and “audio-visual synesthesia.” R-MDMA at both doses produced overall lower subjective effects than MDMA, with significant differences in “drug high,” “happy,” “content,” “talkative,” “open,” “trust,” and “I feel close to others.” The substances were administered at t = 0 h. The data are expressed as the mean ± SEM percentage of maximally possible scores in 24 participants. The corresponding maximal responses and statistics are shown in Table 1.
Fig. 2
Fig. 2. Acute mystical-type experiences on the 5 Dimensions of Altered States of Consciousness (5D-ASC) scale.
MDMA, S-MDMA, and 250 mg R-MDMA induced comparable alterations of mind. The data are expressed as the mean ± SEM percentage of maximally possible scale scores in 24 participants. Statistics are shown in Supplementary Table S5.
Fig. 3
Fig. 3. Acute autonomic effects.
S-MDMA induced greater increases in blood pressure compared with MDMA and both R-MDMA doses. MDMA, S-MDMA, and 250 mg R-MDMA increased heart rate and body temperature comparably. The substances were administered at t = 0 h. The data are expressed mean ± SEM in 24 participants. The corresponding maximal responses and statistics are shown in Table 1.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Atila C, Holze F, Murugesu R, Rommers N, Hutter N, Varghese N, et al. Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial. Lancet Diabetes Endocrinol. 2023;11:454–64. - PubMed
    1. Hysek CM, Schmid Y, Simmler LD, Domes G, Heinrichs M, Eisenegger C, et al. MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci. 2014;9:1645–52. - PMC - PubMed
    1. Mitchell, Ot’alora GM JM, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29:2473–80. - PMC - PubMed
    1. Verrico CD, Miller GM, Madras BK. MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology. 2007;189:489–503. - PubMed
    1. Hiramatsu M, Cho AK. Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: an in vivo microdialysis study. Neuropharmacology. 1990;29:269–75. - PubMed

Publication types

Associated data